oxidized LDL

By Targets:	LOX-1 (1) Antibiotic (1) Apoptosis (1) Bacterial (1) Biochemical Assay Reagents (1) ERK (1) Ferroptosis (2) Fungal (1) Glutathione Peroxidase (2) Interleukin Related (1) LDLR (4) NF-κB (1) p38 MAPK (1) Proton Pump (1) Pyroptosis (1) Reactive Oxygen Species (ROS) (3) Reference Standards (1) Scavenger Receptor Class B type I (SR-BI） (1) Transmembrane Glycoprotein (1)
By Research Areas:	Cardiovascular Disease (6) Infection (1) Inflammation/Immunology (5) Metabolic Disease (1) Neurological Disease (1)

Targets Recommended: LOX-1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-NP013

Oxidized low density lipoprotein (mouse) 1 Publications Verification Mouse ox-LDL	LDLR	Cardiovascular Disease
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

HY-139414

Lysophosphatidylcholines 2 Publications Verification	Interleukin Related p38 MAPK ERK Apoptosis	Inflammation/Immunology
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

HY-126726

KOdiA-PC	Biochemical Assay Reagents	Others
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

HY-23999

BI-0115 2 Publications Verification	LOX-1	Cardiovascular Disease
BI-0115 is a selective inhibitor of LOX-1 (IC₅₀=5.4 μM) that blocks cellular uptake of oxLDL. BI-0115 binding triggers receptor inhibition by formation of dimers of the homodimeric ligand binding domain .

HY-N6738

Bafilomycin B1	Antibiotic Bacterial Fungal Proton Pump	Infection Neurological Disease
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets .

HY-125554

KDdiA-PC	Transmembrane Glycoprotein	Cardiovascular Disease
KDdiA-PC is one of the most potent CD36 ligands in oxidized LDL (oxLDL) .

HY-N10638

N-Acetyldopamine dimer-2	Reactive Oxygen Species (ROS) NF-κB	Inflammation/Immunology
N-Acetyldopamine dimer-2 (compound 2) is a N-acetyldopamine dimer that can be isolated from the yellow powder form Periostracum Cicadae with antioxidant and anti-inflammatory activities. N-Acetyldopamine dimer-2 inhibits oxidized low-density lipoprotein (LDL) oxidation, ROS generation, NO production, and NF-κB activity .

HY-173234

GI-Y2	Pyroptosis	Cardiovascular Disease
GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis .

HY-168371

1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC	Scavenger Receptor Class B type I (SR-BI）	Metabolic Disease
1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC (13-HODE-PC) is an oxidized phospholipid that contains Palmitic acid (HY-N0830) and 13(S)-HODE (HY-113884B) at the sn-1 and sn-2 positions, respectively. 1-Palmitoyl-2-13(S)-HODE-sn-glycero-3-PC has the ability to compete for the binding of 125I-NO2-LDL (5 g/mL) to CD36-transfected 293 cells, with the IC₅₀ of ＞ 200 μM .

HY-W015600

2-Acetamidophenol Orthocetamol	Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

HY-W015600R

2-Acetamidophenol (Standard) Orthocetamol (Standard)	Reference Standards Ferroptosis Glutathione Peroxidase Reactive Oxygen Species (ROS) LDLR	Cardiovascular Disease Inflammation/Immunology
2-Acetamidophenol (Standard) is the analytical standard of 2-Acetamidophenol. This product is intended for research and analytical applications. 2-Acetamidophenol (Orthocetamol) is a regulator that targets ferroptosis and glutathione metabolic pathways, is the ortho-regioisomer of Paracetamol (HY-66005). 2-Acetamidophenol has anti-atherosclerotic activity, and inhibiting total cholesterol (TC) and triglyceride (TG) in a zebrafish hyperlipidemia model with IC₅₀s for 30 μM and 40 μM, respectively. 2-Acetamidophenol upregulates the expression of glutathione synthesis-related genes (such as GCLC, GCLM, GSS) and iron ion transport genes (such as FPN1, FTH), reduces the accumulation of intracellular reactive oxygen species (ROS) and ferrous ions (Fe ²⁺), and enhances the activity of glutathione peroxidase GPX4, thereby inhibiting macrophage phagocytosis of oxidized low-density lipoprotein (ox-LDL) and foam cell formation .

Cat. No.	Product Name	Type

HY-NP013

Oxidized low density lipoprotein (mouse) 1 Publications Verification Mouse ox-LDL	Native Proteins
Oxidized low density lipoprotein (mouse) is an oxidized low density lipoprotein (LDL). Oxidized low density lipoprotein (mouse) induces atherosclerosis (AS) by facilitating endothelial dysfunction and accelerating the VSMCs growth and migration .

HY-139414

Lysophosphatidylcholines 2 Publications Verification	Cell Assay Reagents
Lysophosphatidylcholines is an orally active lysolipid and a component of oxidized low density lipoprotein (LDL). Lysophosphatidylcholines induces cell injury, the production of IL-1β and apoptosis. Lysophosphatidylcholines has a proactive effect on sepsis .

HY-126726

KOdiA-PC	Drug Delivery
Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

KOdiA-PC

Drug Delivery

Oxidized low-density lipoprotein (oxLDL) particles contain low molecular weight species that are cytotoxic and proatherogenic. Many of these species were recently isolated and purified from oxLDL and identified as phosphatidylcholine species containing fragmented oxidized short-chain fatty acid residues at the sn-2 position. 1-(Palmitoyl)-2-(5-keto-6-octene-dioyl)phosphatidylcholine or KOdiA-PC is one of the most potent CD36 ligands of the oxLDL species. KOdiA-PC confers CD36 scavenger receptor binding affinity to LDL at a frequency of only 2 to 3 KOdiA-PC molecules/LDL particle and may be one of the more important structural determinants of oxLDL.

Cat. No.	Product Name	Target	Research Area

HY-P99793

Orticumab MLDL1278A	LDLR	Inflammation/Immunology
Orticumab (MLDL1278A) is an antibody targeting to oxidized or malondialdehyde-modified lipoprotein (LDL). Orticumab specifically inhibits oxidized low-density lipoproteins (oxLDL). Orticumab involves in modulation of autoimmune responses against oxLDL, improves atherosclerosis in animal model. Orticumab also can be used for research of psoriasis improvement .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6738

Bafilomycin B1	Infection Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Source classification Antibacterial Disease Research Disease Research Fields	Antibiotic Bacterial Fungal Proton Pump
Bafilomycin B1 is a macrolide antibiotic that can be isolated from mycelium of Streptomyces gresuis. Bafilomycin B1 is neuroprotective against Chloroquine (HY-17589A)-induced death. Bafilomycin B1 is a structural analog of Bafilomycin A1 and has the ability to inhibit V-ATPase. Bafilomycin B1 inhibits significantly the oxidized low density lipoprotein (LDL)-induced accumulation of lipid droplets .

Recombinant Proteins Recommended:

Oxidized LDL

Species:	Human (2)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P71180

	LOX-1/OLR1 Protein, Human (HEK293, His) oxidized Low-Density Lipoprotein Receptor 1; Ox-LDL Receptor 1; C-Type Lectin Domain Family 8 Member A; Lectin-Like oxidized LDL Receptor 1; LOX-1; Lectin-Like oxLDL Receptor 1; hLOX-1; Lectin-Type oxidized LDL Receptor 1; OLR1; CLEC8A; LOX1	Human	HEK293
	The OLR1 protein is a receptor on vascular endothelial cells that plays a key role in the recognition, internalization, and degradation of oxidatively modified low-density lipoprotein (oxLDL). As a marker of atherosclerosis, oxLDL induces activation of vascular endothelial cells, leading to proinflammatory responses, oxidative conditions, and apoptosis. OLR1 Protein, Human (HEK293, His) is the recombinant human-derived OLR1 protein, expressed by HEK293 , with C-6*His labeled tag.

HY-P71369

	TINAGL1 Protein, Human (HEK293, His) Tubulointerstitial nephritis antigen-like (TINAGL1); also known as Glucocorticoid-inducible protein 5; oxidized LDL-responsive gene 2 protein; TIN Ag-related protein; Tubulointerstitial nephritis antigen-related protein; GIS5; LCN7; OLRG2 and TINAGL	Human	HEK293
	TINAGL1 Protein, implicated in adrenocortical zonation, may regulate distinct adrenal cortex zones and repress CYP11B1 gene expression in adrenocortical cells. As a member of the non-catalytic peptidase C1 family, its distinctive function does not involve enzymatic activity. Unraveling TINAGL1's molecular pathways could offer insights into its role in adrenal physiology, shedding light on its potential to manipulate adrenal function. TINAGL1 Protein, Human (HEK293, His) is the recombinant human-derived TINAGL1 protein, expressed by HEK293 , with C-6*His labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81166

	ox-LDL Antibody ox-LDL: LDL (Copper oxidized); Cu2SO4 oxidized low density lipoprotein; oxidized low density lipoprotein; Low density lipoprotein; MDA oxidized LDL; MDA oxidized low density lipoprotein. 氧化型低密度脂蛋白;	ELISA, IHC-P, IHC-F, FC, ICC/IF	Human
	ox-LDL Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-ox-LDL polyclonal antibody. ox-LDL Antibody can be used for: ELISA, IHC-P, IHC-F, Flow-Cyt, IF expriments in human, background without labeling.

HY-P81172

	LOX 1 Antibody Lectin-type oxidized LDL receptor 1; OLR1; lectin-like low density lipoprotein receptor-1; oxidized low-density lipoprotein receptor 1; Ox-LDL receptor 1; Lectin-like oxidized LDL receptor 1; Lectin-like oxLDL receptor 1; LOX-1; BLOX1; Contains: oxidized low-density lipoprotein receptor 1, soluble form A; oxidized low-density lipoprotein receptor 1, soluble form B; OLR1_HUMAN.	WB, IHC-P, ICC/IF, FC	Human, Rat, Rabbit
	LOX 1 Antibody is an unconjugated, approximately 31 kDa, rabbit-derived, anti-LOX 1 polyclonal antibody. LOX 1 Antibody can be used for: WB, IF-Cell, IHC-P, FC expriments in human, mouse background without labeling.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Biochemical Assay Reagents

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies